358 related articles for article (PubMed ID: 31196128)
1. The impact of sirolimus therapy on lesion size, clinical symptoms, and quality of life of patients with lymphatic anomalies.
Ozeki M; Nozawa A; Yasue S; Endo S; Asada R; Hashimoto H; Fukao T
Orphanet J Rare Dis; 2019 Jun; 14(1):141. PubMed ID: 31196128
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of systemic sirolimus in the treatment of generalized lymphatic anomaly and Gorham-Stout disease.
Ricci KW; Hammill AM; Mobberley-Schuman P; Nelson SC; Blatt J; Bender JLG; McCuaig CC; Synakiewicz A; Frieden IJ; Adams DM
Pediatr Blood Cancer; 2019 May; 66(5):e27614. PubMed ID: 30672136
[TBL] [Abstract][Full Text] [Related]
3. Sirolimus in the Treatment of Vascular Anomalies.
Triana P; Dore M; Cerezo VN; Cervantes M; Sánchez AV; Ferrero MM; González MD; Lopez-Gutierrez JC
Eur J Pediatr Surg; 2017 Feb; 27(1):86-90. PubMed ID: 27723921
[No Abstract] [Full Text] [Related]
4. Sirolimus treatment for intractable lymphatic anomalies: an open-label, single-arm, multicenter, prospective trial.
Ozeki M; Endo S; Yasue S; Nozawa A; Asada R; Saito AM; Hashimoto H; Fujimura T; Yamada Y; Kuroda T; Ueno S; Watanabe S; Nosaka S; Miyasaka M; Umezawa A; Matsuoka K; Maekawa T; Hirakawa S; Furukawa T; Fumino S; Tajiri T; Takemoto J; Souzaki R; Kinoshita Y; Fujino A
Front Med (Lausanne); 2024; 11():1335469. PubMed ID: 38390569
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of sirolimus treatment for intractable lymphatic anomalies: A study protocol for an open-label, single-arm, multicenter, prospective study (SILA).
Ozeki M; Asada R; Saito AM; Hashimoto H; Fujimura T; Kuroda T; Ueno S; Watanabe S; Nosaka S; Miyasaka M; Umezawa A; Matsuoka K; Maekawa T; Yamada Y; Fujino A; Hirakawa S; Furukawa T; Tajiri T; Kinoshita Y; Souzaki R; Fukao T
Regen Ther; 2019 Jun; 10():84-91. PubMed ID: 30705924
[TBL] [Abstract][Full Text] [Related]
6. Oral Sirolimus: An Option in the Management of Neonates with Life-Threatening Upper Airway Lymphatic Malformations.
Triana P; Miguel M; Díaz M; Cabrera M; López Gutiérrez JC
Lymphat Res Biol; 2019 Oct; 17(5):504-511. PubMed ID: 30985248
[No Abstract] [Full Text] [Related]
7. Treatment of Lymphatic Malformations with the mTOR Inhibitor Sirolimus: A Systematic Review.
Wiegand S; Wichmann G; Dietz A
Lymphat Res Biol; 2018 Aug; 16(4):330-339. PubMed ID: 29924669
[TBL] [Abstract][Full Text] [Related]
8. Clinical and radiological improvement in Gorham-Stout disease after sirolimus treatment.
Barnes-Saldaña F; Venegas-Andrade A; Colin-Martínez Ó; Lizardo-Rodríguez A; García-Romero MT; Durán-McKinster C
Bol Med Hosp Infant Mex; 2023; 80(3):217-221. PubMed ID: 37467447
[TBL] [Abstract][Full Text] [Related]
9. How we approach the diagnosis and management of complex lymphatic anomalies.
Ricci KW; Iacobas I
Pediatr Blood Cancer; 2022 Aug; 69 Suppl 3():e28985. PubMed ID: 33844431
[TBL] [Abstract][Full Text] [Related]
10. Severe adverse events during sirolimus "off-label" therapy for vascular anomalies.
Rössler J; Baselga E; Davila V; Celis V; Diociaiuti A; El Hachem M; Mestre S; Haeberli D; Prokop A; Hanke C; Loichinger W; Quéré I; Baumgartner I; Niemeyer CM; Kapp FG
Pediatr Blood Cancer; 2021 Aug; 68(8):e28936. PubMed ID: 33580918
[TBL] [Abstract][Full Text] [Related]
11. [Our experience with sirolimus for the treatment of complicated vascular anomalies].
Giménez-Aleixandre C; Méndez-Aguirre NA; Martínez-Menchón T; Girón Vallejo Ó; Fernández-Ibieta M; Ferri-Ñíguez B; Villamil V; Sánchez-Sánchez Á; Montoya-Rangel CA; Hernández-Bermejo JP
Cir Pediatr; 2019 Jan; 32(1):28-33. PubMed ID: 30714698
[TBL] [Abstract][Full Text] [Related]
12. Topical sirolimus 0.1% for treating cutaneous microcystic lymphatic malformations in children and adults (TOPICAL): protocol for a multicenter phase 2, within-person, randomized, double-blind, vehicle-controlled clinical trial.
Leducq S; Caille A; Barbarot S; Bénéton N; Bessis D; Boccara O; Bursztejn AC; Chiaverini C; Dompmartin A; Droitcourt C; Gissot V; Goga D; Guibaud L; Herbreteau D; Le Touze A; Léauté-Labrèze C; Lorette G; Mallet S; Martin L; Mazereeuw-Hautier J; Phan A; Plantin P; Quéré I; Vabres P; Bourgoin H; Giraudeau B; Maruani A;
Trials; 2019 Dec; 20(1):739. PubMed ID: 31847908
[TBL] [Abstract][Full Text] [Related]
13. Clinical Features and Prognosis of Generalized Lymphatic Anomaly, Kaposiform Lymphangiomatosis, and Gorham-Stout Disease.
Ozeki M; Fujino A; Matsuoka K; Nosaka S; Kuroda T; Fukao T
Pediatr Blood Cancer; 2016 May; 63(5):832-8. PubMed ID: 26806875
[TBL] [Abstract][Full Text] [Related]
14. Treatment of superficial vascular anomalies with topical sirolimus: A multicenter case series.
Dodds M; Tollefson M; Castelo-Soccio L; Garzon MC; Hogeling M; Hook K; Boull C; Maguiness S
Pediatr Dermatol; 2020 Mar; 37(2):272-277. PubMed ID: 31957126
[TBL] [Abstract][Full Text] [Related]
15. Topical sirolimus for the treatment of cutaneous manifestations of vascular anomalies: A case series.
Badia P; Ricci K; Gurria JP; Dasgupta R; Patel M; Hammill A
Pediatr Blood Cancer; 2020 Apr; 67(4):e28088. PubMed ID: 31930696
[TBL] [Abstract][Full Text] [Related]
16. Sirolimus (Rapamycin) for Slow-Flow Malformations in Children: The Observational-Phase Randomized Clinical PERFORMUS Trial.
Maruani A; Tavernier E; Boccara O; Mazereeuw-Hautier J; Leducq S; Bessis D; Guibaud L; Vabres P; Carmignac V; Mallet S; Barbarot S; Chiaverini C; Droitcourt C; Bursztejn AC; Lengellé C; Woillard JB; Herbreteau D; Le Touze A; Joly A; Léauté-Labrèze C; Powell J; Bourgoin H; Gissot V; Giraudeau B; Morel B
JAMA Dermatol; 2021 Nov; 157(11):1289-1298. PubMed ID: 34524406
[TBL] [Abstract][Full Text] [Related]
17. Sirolimus is efficacious in treatment for extensive and/or complex slow-flow vascular malformations: a monocentric prospective phase II study.
Hammer J; Seront E; Duez S; Dupont S; Van Damme A; Schmitz S; Hoyoux C; Chopinet C; Clapuyt P; Hammer F; Vikkula M; Boon LM
Orphanet J Rare Dis; 2018 Oct; 13(1):191. PubMed ID: 30373605
[TBL] [Abstract][Full Text] [Related]
18. Sirolimus treatment for paediatric head and neck lymphatic malformations: a systematic review.
Saibene AM; Rosso C; Felisati G; Pignataro L; Schindler A; Ghilardi G; Colletti G; Gaffuri M; Mozzanica F
Eur Arch Otorhinolaryngol; 2023 Aug; 280(8):3529-3540. PubMed ID: 37115326
[TBL] [Abstract][Full Text] [Related]
19. Generalized lymphatic anomaly successfully treated with long-term, low-dose sirolimus.
Dvorakova V; Rea D; O'Regan GM; Irvine AD
Pediatr Dermatol; 2018 Jul; 35(4):533-534. PubMed ID: 29582448
[TBL] [Abstract][Full Text] [Related]
20. MRI for Response Assessment of Extensive Lymphatic Malformations in Children Treated With Sirolimus.
Durand R; Reid JR; Belasco JB; Shellikeri S; Calle-Toro JS; Cahill AM; Srinivasan A
AJR Am J Roentgenol; 2021 Sep; 217(3):741-752. PubMed ID: 33405944
[No Abstract] [Full Text] [Related]
[Next] [New Search]
